0 results available. Select is focused ,type to refine list, press Down to open the menu,
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company’s lead drug candidate is Onvansertib, an oral, small molecu...
The following section summarizes insights on Cardiff Oncology Inc's EV / Free Cash Flow:
We've identified the following companies as similar to Cardiff Oncology Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EV / Free Cash Flow in the valuation category include:
Measures the dollars in Enterprise Value for each dollar of free cash flow over the last twelve months.
Enterprise Value / Free Cash Flow measures the dollars in Enterprise Value for each dollar of unlevered free cash flow earned over the last 12 months.
TEV / UFCF = Total Enterprise Value / Unlevered Free Cash Flow
Applying this formula, Cardiff Oncology’s EV/FCF is calculated below:
Total Enterprise Value [ $128.6 M ]
(/) Unlevered Free Cash Flow [ -$39.266 M ]
(=) TEV / UFCF [ −3.3x ]
The tables below summarizes the trend in Cardiff Oncology’s EV/FCF over the last five years:
| Date | Enterprise Value | Unlevered Free Cash Flow | TEV / UFCF |
|---|---|---|---|
| 2020-12-31 | $681.9 M | -$16.033 M | −42.5 |
| 2021-12-31 | $137.3 M | -$26.751 M | −5.1 |
| 2022-12-31 | NA | -$34.672 M | NM |
| 2023-12-31 | NA | -$33.194 M | NM |
| 2024-12-31 | $128.6 M | -$39.266 M | −3.3 |
Read more about total enterprise value (tev) and unlevered free cash flow
The chart above depicts the distribution of ev / free cash flow for companies operating in the Healthcare sector in the Developed economic region. Over 2,190 companies were considered in this analysis, and 2,105 had meaningful values. The average ev / free cash flow of companies in the sector is -0.8x with a standard deviation of 26.4x.
Cardiff Oncology Inc's EV / Free Cash Flow of -3.3x ranks in the 40.5% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,193 |
| Included Constituents | 2,105 |
| Min | -125.4x |
| Max | 107.5x |
| Median | -1.7x |
| Mean | -0.8x |
| Standard Deviation | 26.4x |
You can find companies with similar ev / free cash flow using this stock screener.